Published in Mol Ther on July 06, 2010
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med (2012) 5.46
Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer (2011) 5.12
miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet (2012) 2.89
Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics. Nat Nanotechnol (2011) 2.09
Mir-34: a new weapon against cancer? Mol Ther Nucleic Acids (2014) 1.81
Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov (2014) 1.61
miR-34: from bench to bedside. Oncotarget (2014) 1.59
In vivo gene delivery by nonviral vectors: overcoming hurdles? Mol Ther (2012) 1.59
Progress in microRNA delivery. J Control Release (2013) 1.58
miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res (2011) 1.51
Ultrastable synergistic tetravalent RNA nanoparticles for targeting to cancers. Nano Today (2012) 1.39
MicroRNA Involvement in Osteosarcoma. Sarcoma (2012) 1.38
Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. J Control Release (2014) 1.32
Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clin Cancer Res (2013) 1.30
ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression. J Clin Invest (2012) 1.29
In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Adv Drug Deliv Rev (2014) 1.28
MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma. BMC Cancer (2011) 1.25
MicroRNA delivery by cationic lipoplexes for lung cancer therapy. Mol Pharm (2011) 1.25
Therapeutic Delivery of MicroRNA-29b by Cationic Lipoplexes for Lung Cancer. Mol Ther Nucleic Acids (2013) 1.14
Multifunctional iron oxide nanoparticles for diagnostics, therapy and macromolecule delivery. Theranostics (2013) 1.14
Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. Mol Ther (2013) 1.12
siRNA Versus miRNA as Therapeutics for Gene Silencing. Mol Ther Nucleic Acids (2015) 1.12
Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers. ACS Nano (2012) 1.08
Regulation of cancer aggressive features in melanoma cells by microRNAs. PLoS One (2011) 1.07
Lipid-based nanoparticle delivery of Pre-miR-107 inhibits the tumorigenicity of head and neck squamous cell carcinoma. Mol Ther (2012) 1.06
Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. J Drug Deliv (2013) 1.06
Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles. PLoS One (2012) 1.06
Mechanistic Roles of Noncoding RNAs in Lung Cancer Biology and Their Clinical Implications. Genet Res Int (2012) 1.03
Alpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K/AKT pathway. J Hematol Oncol (2015) 1.01
Applications of nanotechnology in dermatology. J Invest Dermatol (2012) 1.00
MicroRNAs and lung cancers: from pathogenesis to clinical implications. Front Med (2012) 1.00
Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer (2016) 0.99
Overexpression of miR-155 causes expansion, arrest in terminal differentiation and functional activation of mouse natural killer cells. Blood (2013) 0.98
MicroRNAs in lung cancer. World J Methodol (2014) 0.97
microRNA therapies in cancer. Mol Cell Ther (2014) 0.95
Drug delivery systems, CNS protection, and the blood brain barrier. Biomed Res Int (2014) 0.95
Associated features in females with an FMR1 premutation. J Neurodev Disord (2014) 0.94
Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma. J Control Release (2013) 0.94
Emerging therapeutic biomarkers in endometrial cancer. Biomed Res Int (2013) 0.93
MicroRNA regulation and therapeutic targeting of survivin in cancer. Am J Cancer Res (2014) 0.93
Lipid nanoparticles for hepatic delivery of small interfering RNA. Biomaterials (2012) 0.93
MicroRNA as tools and therapeutics in lung cancer. Respir Med (2015) 0.93
RNAi Therapeutic Platforms for Lung Diseases. Pharmaceuticals (Basel) (2013) 0.92
Delivery of RNA nanoparticles into colorectal cancer metastases following systemic administration. ACS Nano (2015) 0.92
Attenuation of mouse melanoma by A/C magnetic field after delivery of bi-magnetic nanoparticles by neural progenitor cells. ACS Nano (2010) 0.91
MicroRNAs as therapeutic targets in human cancers. Wiley Interdiscip Rev RNA (2014) 0.91
Entropy-driven one-step formation of Phi29 pRNA 3WJ from three RNA fragments. Biochemistry (2014) 0.91
MicroRNAs in cancer diagnosis and therapy: from bench to bedside. Surg Today (2012) 0.90
A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA. Mol Ther (2011) 0.90
ACVR1, a therapeutic target of fibrodysplasia ossificans progressiva, is negatively regulated by miR-148a. Int J Mol Sci (2012) 0.90
The effects of MicroRNA transfections on global patterns of gene expression in ovarian cancer cells are functionally coordinated. BMC Med Genomics (2012) 0.90
MicroRNAS in endometrial cancer: recent advances and potential clinical applications. EXCLI J (2015) 0.89
Noncoding RNAs: key molecules in understanding and treating pain. Trends Mol Med (2014) 0.89
MicroRNAs in Head and Neck Cancer. Int J Dent (2013) 0.88
All's well that transcribes well: non-coding RNAs and post-stroke brain damage. Neurochem Int (2013) 0.88
Delivery of intracellular-acting biologics in pro-apoptotic therapies. Curr Pharm Des (2011) 0.87
Site-specific antibody-polymer conjugates for siRNA delivery. J Am Chem Soc (2013) 0.87
Gold nano-particles (AuNPs) carrying anti-EBV-miR-BART7-3p inhibit growth of EBV-positive nasopharyngeal carcinoma. Oncotarget (2015) 0.87
MicroRNA in carcinogenesis & cancer diagnostics: a new paradigm. Indian J Med Res (2013) 0.86
Transferrin coated nanoparticles: study of the bionano interface in human plasma. PLoS One (2012) 0.86
Targeted delivery of siRNA-generating DNA nanocassettes using multifunctional nanoparticles. Small (2013) 0.86
Regulation of cancer metastasis by microRNAs. J Biomed Sci (2015) 0.86
Self-assembled RNA-triple-helix hydrogel scaffold for microRNA modulation in the tumour microenvironment. Nat Mater (2015) 0.86
p53-Regulated Networks of Protein, mRNA, miRNA, and lncRNA Expression Revealed by Integrated Pulsed Stable Isotope Labeling With Amino Acids in Cell Culture (pSILAC) and Next Generation Sequencing (NGS) Analyses. Mol Cell Proteomics (2015) 0.86
Anti-tumor Efficiency of Lipid-coated Cisplatin Nanoparticles Co-loaded with MicroRNA-375. Theranostics (2016) 0.85
Non-coding RNAs as theranostics in human cancers. J Cell Biochem (2012) 0.85
Targeted delivery of let-7a microRNA encapsulated ephrin-A1 conjugated liposomal nanoparticles inhibit tumor growth in lung cancer. Int J Nanomedicine (2013) 0.85
miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents. Future Med Chem (2014) 0.84
Smoking and microRNA dysregulation: a cancerous combination. Trends Mol Med (2013) 0.83
MicroRNAs in Liver Health and Disease. Curr Pathobiol Rep (2013) 0.83
Phospholipid-modified PEI-based nanocarriers for in vivo siRNA therapeutics against multidrug-resistant tumors. Gene Ther (2014) 0.83
miRNA: the new frontier in cancer medicine. Future Med Chem (2013) 0.83
Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy. Ther Deliv (2012) 0.83
The potential clinical applications and prospects of microRNAs in lung cancer. Onco Targets Ther (2014) 0.82
Theranostic nanoparticles carrying doxorubicin attenuate targeting ligand specific antibody responses following systemic delivery. Theranostics (2015) 0.82
Role and Function of MicroRNAs in Extracellular Vesicles in Cardiovascular Biology. Biomed Res Int (2015) 0.82
Development of drug loaded nanoparticles for tumor targeting. Part 1: Synthesis, characterization, and biological evaluation in 2D cell cultures. Nanoscale (2013) 0.81
Lipid-based vectors for siRNA delivery. J Drug Target (2012) 0.81
MicroRNAs and cancer therapeutics. Pharm Res (2011) 0.81
Clinical Significance of MicroRNA Expression Profiles and Polymorphisms in Lung Cancer Development and Management. Patholog Res Int (2011) 0.81
Effect of surface properties on liposomal siRNA delivery. Biomaterials (2015) 0.80
MicroRNA Therapeutics: the Next Magic Bullet? Mini Rev Med Chem (2015) 0.80
Non-coding landscapes of colorectal cancer. World J Gastroenterol (2015) 0.80
Development of MicroRNA Therapeutics for Hepatocellular Carcinoma. Diagnostics (Basel) (2013) 0.80
Recent Developments in Active Tumor Targeted Multifunctional Nanoparticles for Combination Chemotherapy in Cancer Treatment and Imaging. J Biomed Nanotechnol (2015) 0.80
Identification of FLOT2 as a novel target for microRNA-34a in melanoma. J Cancer Res Clin Oncol (2014) 0.79
Non-viral nucleic acid containing nanoparticles as cancer therapeutics. Expert Opin Drug Deliv (2016) 0.79
Targeted delivery of chemically modified anti-miR-221 to hepatocellular carcinoma with negatively charged liposomes. Int J Nanomedicine (2015) 0.79
Polymeric nanoparticle-based delivery of microRNA-199a-3p inhibits proliferation and growth of osteosarcoma cells. Int J Nanomedicine (2015) 0.79
Manipulating miRNA Expression: A Novel Approach for Colon Cancer Prevention and Chemotherapy. Curr Pharmacol Rep (2015) 0.79
Targeting of phage particles towards endothelial cells by antibodies selected through a multi-parameter selection strategy. Sci Rep (2017) 0.79
Targeted polymeric nanoparticles for cancer gene therapy. J Drug Target (2015) 0.78
MicroRNA-877 acts as a tumor suppressor by directly targeting eEF2K in renal cell carcinoma. Oncol Lett (2015) 0.78
Grand Challenges and Opportunities in Deciphering the Role of Non-Coding RNAs in Human Diseases. Front Genet (2011) 0.78
Advances in biomimetic regeneration of elastic matrix structures. Drug Deliv Transl Res (2012) 0.78
Coating Solid Lipid Nanoparticles with Hyaluronic Acid Enhances Antitumor Activity against Melanoma Stem-like Cells. Theranostics (2015) 0.78
Retracted siRNA-participated chemotherapy: an efficient and specific therapeutic against gastric cancer. J Cancer Res Clin Oncol (2013) 0.78
Cancer subtypes classification using long non-coding RNA. Oncotarget (2016) 0.78
Specific Delivery of MiRNA for High Efficient Inhibition of Prostate Cancer by RNA Nanotechnology. Mol Ther (2016) 0.78
Nanomedicines for Endothelial Disorders. Nano Today (2015) 0.77
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
Silencing of microRNAs in vivo with 'antagomirs'. Nature (2005) 32.56
The promises and pitfalls of RNA-interference-based therapeutics. Nature (2009) 7.53
MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene (2007) 6.55
MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res (2009) 3.57
Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther (2007) 3.03
miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett (2008) 2.81
The MAPK pathway in melanoma. Curr Opin Oncol (2008) 2.80
An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J Control Release (2008) 1.95
MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met. Invest Ophthalmol Vis Sci (2008) 1.80
Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther (2008) 1.74
Clarifications on miRNA and cancer. Science (2006) 1.69
Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma. Cancer Res (2009) 1.34
MicroRNA: biogenetic and functional mechanisms and involvements in cell differentiation and cancer. J Pharmacol Sci (2006) 1.33
MicroRNA therapeutics: a new niche for antisense nucleic acids. Trends Mol Med (2006) 1.29
Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells. Cancer Res (2004) 1.25
Identification of clinically significant tumor antigens by selecting phage antibody library on tumor cells in situ using laser capture microdissection. Mol Cell Proteomics (2006) 1.23
Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells. Mol Cancer Ther (2007) 1.22
Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells. Mol Pharm (2009) 1.21
Primer extension-based method for the generation of a siRNA/miRNA expression vector. Physiol Genomics (2007) 1.21
Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies. Mol Cancer Ther (2008) 1.04
Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine. Int J Cancer (2005) 1.03
Enhancement of survivin gene downregulation and cell apoptosis by a novel combination: liposome microbubbles and ultrasound exposure. Med Oncol (2009) 0.95
Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion. J Mol Med (Berl) (2009) 0.92
Identification of internalizing human single-chain antibodies targeting brain tumor sphere cells. Mol Cancer Ther (2010) 0.91
High affinity single-chain Fv antibody fragments protecting the human nicotinic acetylcholine receptor. J Neuroimmunol (1999) 0.85
Construction of human ScFv phage display library against ovarian tumor. J Huazhong Univ Sci Technolog Med Sci (2006) 0.82
siRNAs: a new wave of RNA-based therapeutics. J Antimicrob Chemother (2003) 0.81
A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science (2002) 42.78
The Genomes of Oryza sativa: a history of duplications. PLoS Biol (2005) 7.67
A draft sequence for the genome of the domesticated silkworm (Bombyx mori). Science (2004) 6.62
Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol (2003) 5.77
A genetic variation map for chicken with 2.8 million single-nucleotide polymorphisms. Nature (2004) 5.24
Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm (2008) 3.92
Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem (2002) 3.14
Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther (2007) 3.03
Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54. Nat Genet (2010) 2.95
Validation of internal control for gene expression study in soybean by quantitative real-time PCR. BMC Mol Biol (2008) 2.94
NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J Biol Chem (2003) 2.92
Genome-wide analysis for discovery of rice microRNAs reveals natural antisense microRNAs (nat-miRNAs). Proc Natl Acad Sci U S A (2008) 2.92
Functional genetic analysis of mouse chromosome 11. Nature (2003) 2.87
Michigan Molecular Interactions (MiMI): putting the jigsaw puzzle together. Nucleic Acids Res (2006) 2.77
Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J Clin Oncol (2013) 2.69
Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat Rev Immunol (2005) 2.59
Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias. Circulation (2007) 2.50
Pigs in sequence space: a 0.66X coverage pig genome survey based on shotgun sequencing. BMC Genomics (2005) 2.34
Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer (2004) 2.31
Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev (2009) 2.28
Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol Pharm (2006) 2.28
Mesoscopic CH3NH3PbI3/TiO2 heterojunction solar cells. J Am Chem Soc (2012) 2.17
(Z)-Ethyl 2,4-diphenyl-3-(propyl-amino)-but-2-enoate. Acta Crystallogr Sect E Struct Rep Online (2009) 2.09
The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med (Berl) (2008) 2.04
The feasibility of measuring renal blood flow using transesophageal echocardiography in patients undergoing cardiac surgery. Anesth Analg (2009) 1.97
An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor. J Control Release (2008) 1.95
Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim Biophys Acta (2009) 1.94
Hysteresis in single-layer MoS2 field effect transistors. ACS Nano (2012) 1.92
Derivation of Escherichia coli O157:H7 from its O55:H7 precursor. PLoS One (2010) 1.90
Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci (2002) 1.87
Cardiac Na+ current regulation by pyridine nucleotides. Circ Res (2009) 1.87
Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol Sci (2003) 1.87
A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther (2003) 1.86
Blue light-dependent interaction of CRY2 with SPA1 regulates COP1 activity and floral initiation in Arabidopsis. Curr Biol (2011) 1.84
Detection of PCC functional connectivity characteristics in resting-state fMRI in mild Alzheimer's disease. Behav Brain Res (2008) 1.83
Gender differences in methamphetamine use and responses: a review. Gend Med (2008) 1.83
Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J (2003) 1.81
Targeted nanoparticles deliver siRNA to melanoma. J Invest Dermatol (2010) 1.81
Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Control Release (2009) 1.76
Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther (2008) 1.74
Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J Neurosci (2003) 1.73
Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J Control Release (2011) 1.72
Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. J Control Release (2007) 1.68
Implications of an antiparallel dimeric structure of nonphosphorylated STAT1 for the activation-inactivation cycle. Proc Natl Acad Sci U S A (2005) 1.68
A germin-like protein gene family functions as a complex quantitative trait locus conferring broad-spectrum disease resistance in rice. Plant Physiol (2008) 1.68
Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice. Hum Gene Ther (2008) 1.65
Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J Control Release (2010) 1.64
In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J Natl Cancer Inst (2002) 1.61
High-efficiency and heritable gene targeting in mouse by transcription activator-like effector nucleases. Nucleic Acids Res (2013) 1.61
In vivo gene delivery by nonviral vectors: overcoming hurdles? Mol Ther (2012) 1.59
Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. J Neurosci (2003) 1.58
Microglia enhance beta-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. J Neurochem (2002) 1.58
Cohort profile: The Guangzhou Biobank Cohort Study, a Guangzhou-Hong Kong-Birmingham collaboration. Int J Epidemiol (2006) 1.58
Non-viral is superior to viral gene delivery. J Control Release (2007) 1.54
Toxoplasma gondii infection in pregnant women in China. Trans R Soc Trop Med Hyg (2008) 1.51
The action mechanisms of plant cryptochromes. Trends Plant Sci (2011) 1.51
Nonviral methods for siRNA delivery. Mol Pharm (2009) 1.50
MiR-26a enhances metastasis potential of lung cancer cells via AKT pathway by targeting PTEN. Biochim Biophys Acta (2012) 1.48
Recent advances in nonviral vectors for gene delivery. Acc Chem Res (2011) 1.48
Arachnoid granulations of middle cranial fossa: a population study between cadaveric dissection and in vivo computed tomography examination. Surg Radiol Anat (2010) 1.47
Gemstone spectral imaging dual-energy computed tomography: a novel technique to determine urinary stone composition. Urology (2013) 1.47
Altered keratin 17 peptide ligands inhibit in vitro proliferation of keratinocytes and T cells isolated from patients with psoriasis. J Am Acad Dermatol (2006) 1.46
Surface-modified LPD nanoparticles for tumor targeting. Ann N Y Acad Sci (2006) 1.46
ChickVD: a sequence variation database for the chicken genome. Nucleic Acids Res (2005) 1.45
Developed and developing world responsibilities for historical climate change and CO2 mitigation. Proc Natl Acad Sci U S A (2012) 1.44
The aged retinal pigment epithelium/choroid: a potential substratum for the pathogenesis of age-related macular degeneration. PLoS One (2008) 1.44
Small RNA-directed epigenetic natural variation in Arabidopsis thaliana. PLoS Genet (2008) 1.43
Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther (2003) 1.43
Roles of DCL4 and DCL3b in rice phased small RNA biogenesis. Plant J (2011) 1.42
Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase. FASEB J (2004) 1.40
Rates of mutation and host transmission for an Escherichia coli clone over 3 years. PLoS One (2011) 1.40
Community-wide assessment of protein-interface modeling suggests improvements to design methodology. J Mol Biol (2011) 1.40
Bioconjugated nanoparticles for DNA protection from cleavage. J Am Chem Soc (2003) 1.39
Porcine transcriptome analysis based on 97 non-normalized cDNA libraries and assembly of 1,021,891 expressed sequence tags. Genome Biol (2007) 1.39
Anti-tumor activity of splice-switching oligonucleotides. Nucleic Acids Res (2010) 1.38
Canonical and atypical E2Fs regulate the mammalian endocycle. Nat Cell Biol (2012) 1.37
Synthesis and herbicidal activity of novel alpha,alpha,alpha-trifluoro-m-tolyl pyridazinone derivatives. Pest Manag Sci (2006) 1.37
Synthesis and application of chiral spiro phospholane ligand in Pd-catalyzed asymmetric allylation of aldehydes with allylic alcohols. Org Lett (2005) 1.37
Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma. Cancer Res (2009) 1.34
Resting brain connectivity: changes during the progress of Alzheimer disease. Radiology (2010) 1.34
The comparison of radiation dose between C-arm flat-detector CT (DynaCT) and multi-slice CT (MSCT): a phantom study. Eur J Radiol (2011) 1.32
Hypoxia-inducible factor (HIF)-1 alpha directly enhances the transcriptional activity of stem cell factor (SCF) in response to hypoxia and epidermal growth factor (EGF). Carcinogenesis (2008) 1.32
Interactive role of the toll-like receptor 4 and reactive oxygen species in LPS-induced microglia activation. Glia (2005) 1.31
Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J Pharmacol Exp Ther (2003) 1.30
Nanostructured calcium phosphates (NanoCaPs) for non-viral gene delivery: influence of the synthesis parameters on transfection efficiency. Biomaterials (2006) 1.30
Assessment of coronary plaque collagen with polarization sensitive optical coherence tomography (PS-OCT). Int J Cardiol (2006) 1.29
Glaucomatous optic neuropathy: when glia misbehave. Neuroscientist (2003) 1.29
Genotypic variants at 2q33 and risk of esophageal squamous cell carcinoma in China: a meta-analysis of genome-wide association studies. Hum Mol Genet (2012) 1.28
NM23-H1 and NM23-H2 repress transcriptional activities of nuclease-hypersensitive elements in the platelet-derived growth factor-A promoter. J Biol Chem (2001) 1.28
Complete nucleotide sequence and organization of the naphthalene catabolic plasmid pND6-1 from Pseudomonas sp. strain ND6. Gene (2004) 1.28
Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem (2010) 1.28
Control of specificity and magnitude of NF-kappa B and STAT1-mediated gene activation through PIASy and PIAS1 cooperation. Proc Natl Acad Sci U S A (2007) 1.28
Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands. J Am Chem Soc (2010) 1.27
Expression of p53, inducible nitric oxide synthase and vascular endothelial growth factor in gastric precancerous and cancerous lesions: correlation with clinical features. BMC Cancer (2002) 1.27
miR-223 regulates migration and invasion by targeting Artemin in human esophageal carcinoma. J Biomed Sci (2011) 1.27
An approach for identifying cytokines based on a novel ensemble classifier. Biomed Res Int (2013) 1.27
The mitochondrial genome of the thermal dimorphic fungus Penicillium marneffei is more closely related to those of molds than yeasts. FEBS Lett (2003) 1.26
The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery. Fundam Clin Pharmacol (2008) 1.26